Charles Calvo, MD
Retina Specialist · Las Vegas, NVNPI 1194087940
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,768 of the $2,240 with a category attached, or 79.0%. It is spread thinly across 15 manufacturers, the largest accounting for just 18.5% — the pattern of someone who eats at a lot of different presentations.
Across 54 payments — averaging $41.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$414
- Regeneron Healthcare Solutions, Inc.$403
- Alimera Sciences, Inc.$245
- Genentech USA, Inc.$242
- Eyepoint US, Inc.$209
- AbbVie$206
- plus $520 from 9 others
Across 11 payments — averaging $7881.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$87K
What the payments were for
- Food & beverage$1,76879%
- Education$783%
- Gifts$39418%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 2 | $414 |
| Regeneron Healthcare Solutions, Inc. | 8 | $403 |
| Alimera Sciences, Inc. | 9 | $245 |
| Genentech USA, Inc. | 10 | $242 |
| Eyepoint US, Inc. | 5 | $209 |
| AbbVie(2 entities) | 5 | $206 |
| Apellis Pharmaceuticals, Inc. | 3 | $132 |
| Regeneron | 1 | $103 |
| Alcon Research LLC | 1 | $67 |
| Bausch & Lomb Americas Inc. | 2 | $46 |
| Boston Scientific | 3 | $44 |
| AstraZeneca | 1 | $43 |
| Biogen | 2 | $40 |
| Optos, Inc. | 1 | $28 |
| Spark Therapeutics, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Constellation$394
- EYLEA$223
- YUTIQ$163
- VABYSMO$121
- EYLEA HD$120
How this compares
Too few retina specialist providers in Nevadato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 46 | $1,624 |
| Ketorolac Tromethamine | 16 | $381 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 15 | $123 |
| Latanoprost | 15 | $112 |
| Brimonidine Tartrate | 12 | $72 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in Las Vegas
- George ParLas Vegas$110K
- Chris WuLas Vegas$11K
- Russell JayneLas Vegas$8K
- Alec AmramLas Vegas$1K
- Tyson WardLas Vegas$1K
- Greggory GahnReno$15K
- Spencer FullerReno$6K
- William StevensonReno$5K
- John GunnHenderson$1K
- Zachary BodnarHenderson$724
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.